π
|
Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study
17 auth.
A. Dennis,
D. Cuthbertson,
D. Wootton,
M. Crooks,
M. Gabbay,
N. Eichert,
S. Mouchti,
M. Pansini,
A. Roca-FernΓ‘ndez,
H. Thomaides-Brears,
...
M. Kelly,
Matthew Robson,
L. Hishmeh,
E. Attree,
M. Heightman,
R. Banerjee,
A. Banerjee
|
5 |
2022 |
5 π
|
π’
|
Mullerian papilloma-like proliferation arising in cystic pelvic endosalpingiosis.
W. Mccluggage,
D. OβRourke,
Clodagh McElhenney,
M. Crooks
|
4 |
2002 |
4 π’
|
π
|
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years.
9 auth.
J. Pope,
L. Bessette,
N. Jones,
L. Fallon,
J. Woolcott,
D. Gruben,
...
M. Crooks,
D. Gold,
B. Haraoui
|
4 |
2019 |
4 π
|
π’
|
Helping the quitters quit: A systematic review and narrative synthesis of the barriers and facilitators to e-cigarette cessation and the support that is needed.
J. Dyson,
M. Bhatnagar,
J. Skinner,
M. Crooks
|
3 |
2021 |
3 π’
|
π¦
|
Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions
10 auth.
M. Crooks,
Lucia Crowther,
H. Cummings,
J. Cohen,
Chao Huang,
A. Morice,
...
S. Faruqi,
Jack Birchall,
Yang Xu,
T. Morris
|
1 |
2021 |
1 π¦
|
π’
|
Carbon footprint of maintenance and reliever therapy (MART) versus maintenance plus SABA (Mx+SABA) regimens for asthma: Results from the healthCARe-Based envirONmental cost of treatment (CARBON) programme
7 auth.
J. Bell,
E. Maslova,
P. Miller,
A. Wilkinson,
C. Janson,
R. Beasley,
...
M. Crooks
|
1 |
2022 |
1 π’
|